<?xml version="1.0" encoding="UTF-8" standalone="yes"?><rss version="2.0">    <channel>        <title>GSK US news</title>        <link>http://www.us-gsk.com/html/media-news/</link>        <description>GlaxoSmithKline is a leading healthcare company that helps people to do more, feel better and live longer. This RSS feed contains press releases and investor news.</description>                    <item>                <title>GSK statement on tender offer to acquire Human Genome Sciences</title>                                    <description><![CDATA[GlaxoSmithKline plc (LSE: GSK) today commented on Human Genome Sciences (NASDAQ: HGSI) Board of Directors’ decision to recommend against GSK’s tender offer to acquire all of the outstanding shares of HGS for US$13.00 per share in cash. The offer represents a premium of 81 percent to HGS’s closing share price of US$7.17 on 18th April, the last trading day before HGS publicly disclosed GSK’s private offer. The offer is not conditioned on due diligence or financing.]]></description>                                <pubDate>Thu, 17 May 2012 16:50:05 GMT</pubDate>                                    <link>http://www.us-gsk.com/html/media-news/pressreleases/2012/2012-pressrelease-1094071.htm</link>                    <guid>http://www.us-gsk.com/html/media-news/pressreleases/2012/2012-pressrelease-1094071.htm</guid>                            </item>                    <item>                <title>GlaxoSmithKline completes transaction to increase its ownership in Theravance</title>                                    <description><![CDATA[GlaxoSmithKline plc (“GSK”) (LSE:GSK) and Theravance, Inc. (“Theravance”) (NASDAQ: THRX) announced today that following approval by Theravance, Inc.‟s stockholders at their Annual Meeting held on 15 May 2012, and expiration of applicable waiting periods under the US Hart-Scott-Rodino Antitrust Improvements Act of 1976, GSK‟s acquisition of 10,000,000 shares of Theravance common stock on the terms previously announced on 2 April 2012, has now completed.]]></description>                                <pubDate>Wed, 16 May 2012 13:21:50 GMT</pubDate>                                    <link>http://www.us-gsk.com/html/media-news/pressreleases/2012/2012-pressrelease-1092377.htm</link>                    <guid>http://www.us-gsk.com/html/media-news/pressreleases/2012/2012-pressrelease-1092377.htm</guid>                            </item>                    <item>                <title>GlaxoSmithKline to fully acquire Cellzome for £61 million</title>                                    <description><![CDATA[GlaxoSmithKline plc (GSK) today announced that it has entered into an agreement to acquire those shares it does not currently own in Cellzome, a leader in the development and advancement of proteomics technologies, for £61 million (US$99 million) in cash. Cellzome, a privately owned company with laboratories in Cambridge, UK, and Heidelberg, Germany, will become part of GSK’s R&D organisation.]]></description>                                <pubDate>Tue, 15 May 2012 09:03:54 GMT</pubDate>                                    <link>http://www.us-gsk.com/html/media-news/pressreleases/2012/2012-pressrelease-1090596.htm</link>                    <guid>http://www.us-gsk.com/html/media-news/pressreleases/2012/2012-pressrelease-1090596.htm</guid>                            </item>                    <item>                <title>Stiefel receives US FDA approval of Fabior™ Foam, 0.1%</title>                                    <description><![CDATA[Stiefel, a GSK (NYSE:GSK) company, today announced that the US Food and Drug Administration has approved the New Drug Application for Fabior (tazarotene) Foam, 0.1%.]]></description>                                <pubDate>Fri, 11 May 2012 23:08:25 GMT</pubDate>                                    <link>http://www.us-gsk.com/html/media-news/pressreleases/2012/2012-pressrelease-1086719.htm</link>                    <guid>http://www.us-gsk.com/html/media-news/pressreleases/2012/2012-pressrelease-1086719.htm</guid>                            </item>                    <item>                <title>GSK commences tender offer to acquire Human Genome Sciences for US $13.00 per share in cash</title>                                    <description><![CDATA[GSK commences tender offer to acquire Human Genome Sciences for US $13.00 per share in cash]]></description>                                <pubDate>Thu, 10 May 2012 11:55:27 GMT</pubDate>                                    <link>http://www.us-gsk.com/html/media-news/pressreleases/2012/2012-pressrelease-1083732.htm</link>                    <guid>http://www.us-gsk.com/html/media-news/pressreleases/2012/2012-pressrelease-1083732.htm</guid>                            </item>                    <item>                <title>GSK to commence tender offer to acquire Human Genome Sciences for US $13.00 per share in cash</title>                                    <description><![CDATA[GSK announced that it will not participate in Human Genome Sciences strategic alternatives review process and will instead commence a tender offer this week to acquire all of the outstanding shares of HGS for US$13.00 per share in cash.  ]]></description>                                <pubDate>Wed, 09 May 2012 06:36:50 GMT</pubDate>                                    <link>http://www.us-gsk.com/html/media-news/pressreleases/2012/2012-pressrelease-1081172.htm</link>                    <guid>http://www.us-gsk.com/html/media-news/pressreleases/2012/2012-pressrelease-1081172.htm</guid>                            </item>                    <item>                <title>GlaxoSmithKline plc appoints two Non-Executive Directors to its Board</title>                                    <description><![CDATA[GlaxoSmithKline plc appoints two Non-Executive Directors to its Board]]></description>                                <pubDate>Thu, 03 May 2012 12:39:24 GMT</pubDate>                                    <link>http://www.us-gsk.com/html/media-news/pressreleases/2012/2012-pressrelease-1073699.htm</link>                    <guid>http://www.us-gsk.com/html/media-news/pressreleases/2012/2012-pressrelease-1073699.htm</guid>                            </item>                    <item>                <title>GlaxoSmithKline and Yale University establish drug discovery collaboration to design potential new class of medicines</title>                                    <description><![CDATA[GlaxoSmithKline and Yale University establish drug discovery collaboration to design potential new class of medicines]]></description>                                <pubDate>Tue, 01 May 2012 12:40:54 GMT</pubDate>                                    <link>http://www.us-gsk.com/html/media-news/pressreleases/2012/2012-pressrelease-1070665.htm</link>                    <guid>http://www.us-gsk.com/html/media-news/pressreleases/2012/2012-pressrelease-1070665.htm</guid>                            </item>                    <item>                <title>Mayor Nutter Announces $1 Million Grant from GSK and The Philadelphia Foundation for Summer Youth Internships</title>                                    <description><![CDATA[During the British American Business Council (BABC) Breakfast with His Royal Highness The Prince Edward in attendance, Mayor Michael A. Nutter announced that $1 million will be provided to support WorkReady Philadelphia programs through grants from pharmaceutical and healthcare company GlaxoSmithKline (GSK) and The Philadelphia Foundation.]]></description>                                <pubDate>Fri, 27 Apr 2012 12:56:05 GMT</pubDate>                                    <link>http://www.us-gsk.com/html/media-news/pressreleases/2012/2012-pressrelease-1066530.htm</link>                    <guid>http://www.us-gsk.com/html/media-news/pressreleases/2012/2012-pressrelease-1066530.htm</guid>                            </item>                    <item>                <title>FDA approves Votrient® for treatment of patients with certain types of advanced soft tissue sarcoma</title>                                    <description><![CDATA[GlaxoSmithKline plc [LSE/NYSE: GSK] announced today that the U.S. Food and Drug Administration (FDA) has approved Votrient® (pazopanib) for the treatment of patients with advanced soft tissue sarcoma who have received prior chemotherapy.]]></description>                                <pubDate>Thu, 26 Apr 2012 22:21:55 GMT</pubDate>                                    <link>http://www.us-gsk.com/html/media-news/pressreleases/2012/2012-pressrelease-1064949.htm</link>                    <guid>http://www.us-gsk.com/html/media-news/pressreleases/2012/2012-pressrelease-1064949.htm</guid>                            </item>                    <item>                <title>GSK and University of Nottingham collaborate to create Centre of Excellence for sustainable chemistry</title>                                    <description><![CDATA[GSK and the University of Nottingham formalised a collaboration to establish a new laboratory to accommodate the Centre of Excellence for sustainable chemistry and to construct an innovative carbon neutral sustainable chemistry laboratory.  ]]></description>                                <pubDate>Thu, 26 Apr 2012 07:49:59 GMT</pubDate>                                    <link>http://www.us-gsk.com/html/media-news/pressreleases/2012/2012-pressrelease-1061820.htm</link>                    <guid>http://www.us-gsk.com/html/media-news/pressreleases/2012/2012-pressrelease-1061820.htm</guid>                            </item>                    <item>                <title>Results announcement for the first quarter 2012</title>                                    <description><![CDATA[Results announcement for the first quarter 2012]]></description>                                <pubDate>Wed, 25 Apr 2012 10:45:01 GMT</pubDate>                                    <link>http://www.us-gsk.com/html/media-news/pressreleases/2012/2012-pressrelease-1060028.htm</link>                    <guid>http://www.us-gsk.com/html/media-news/pressreleases/2012/2012-pressrelease-1060028.htm</guid>                            </item>            </channel></rss>
